Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics presented updated Phase 2 data for EIK1001 in first-line stage 4 NSCLC at ASCO 2026, showing a 63.1% objective response rate and 90.8% disease control rate in combination with pembrolizumab and chemotherapy. The data included a 72.4% ORR in the squamous cohort and a 55.6% ORR in the non-squamous cohort, with a manageable safety profile supporting outpatient administration.
Key figures
- Drug Name
- EIK1001, EIK1003, EIK1005
- Phase Of Trial
- Phase 2 (EIK1001), Phase 1/2 (EIK1003)
- Eik1001 dcr
- 90.8%
- Eik1001 orr
- 63.1%
- Eik1001 participants
- 72
- Eik1001 squamous orr
- 72.4%
- Eik1003 combination orr
- 24.5%
- Eik1003 monotherapy orr
- 14.3%
- Eik1001 non squamous orr
- 55.6%
- Eik1003 combination patients
- 60
- Eik1003 monotherapy patients
- 65
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.